The retirement income gap no-one is talking about

People are living longer than ever before and this can impact how you plan for retirement

Clinuvel Pharmaceuticals Limited (CUV.AX)

ASX - ASX Delayed price. Currency in AUD

Add to watchlist

15.36

-0.03

(-0.19%)

As of 12:51PM AEST. Market open.

Loading interactive chart…

Simply Wall St.
Is Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Clinuvel Pharmaceuticals' (ASX:CUV) stock is up by a considerable 8.7% over the past month. Since the market usually...
GlobeNewswire
Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors
DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE® (afamelanotide) and the future of photomedicine. Over 70 guests discussed the Company’s unique history and future growth potential at an invitation-only event in Düsseldorf. Managing Director and CEO, Dr Philippe Wolgen shared the Company’s success in establishing profitability over the past seven financial years
Simply Wall St.
Clinuvel Pharmaceuticals (ASX:CUV) shareholders have endured a 50% loss from investing in the stock three years ago
Investing in stocks inevitably means buying into some companies that perform poorly. Long term Clinuvel Pharmaceuticals...